Strong Margin Expansion and EPS Growth
Adjusted gross margin reached 36% in Q4, up 320 basis points year-over-year; adjusted operating margin expanded 420 basis points to 16.8%, exceeding the company's 2027 target range. Adjusted EPS for the quarter was $1.11, a 59% increase versus prior year; full-year adjusted EPS growth was ~38%.
Consistent Aftermarket Strength
Aftermarket bookings grew 10% in the quarter to $682 million (seventh consecutive quarter > $600M). Aftermarket sales increased 8% in the quarter and total aftermarket bookings for 2025 were $2.6 billion, +9% year-over-year.
Revenue and Organic Sales Performance
Total revenues in Q4 grew 4% year-over-year to $1.2 billion, with organic sales growth of roughly 1% and a ~240 basis point benefit from foreign currency translation.
Operating Cash Flow and Cash Return to Shareholders
Excluding asbestos divestiture impacts, Q4 cash from operations was $199 million with 121% free cash flow conversion. Full-year operating cash flow was $506 million, a 19% increase versus 2024. Returned $84 million in cash to shareholders in Q4 (including $57 million repurchases) and $365 million for the full year (including $255 million repurchases at an average $53/share); $200 million remains on the repurchase authorization.
Segment Margin Outperformance (FPD and FCD)
FPD adjusted gross margin rose 370 basis points to 37.1% and adjusted operating margin expanded to 21% (+350 bps); FPD bookings +8% with aftermarket +12% and FY Q4 sales of $833 million (FPD book-to-bill 1.06x). FCD adjusted gross margin improved 220 basis points to 34% and adjusted operating margin to 19.7% (+440 bps); Mogas acquisition delivered accretive margins.
2015–2025 Strategic Execution and M&A
Flowserve delivered its 2027 margin target two years ahead of plan and completed successful integrations (Mogas) using the Flowserve Business System. Announced acquisition of Trillium valve and actuation business (installed base >200,000 units, presence in 115 nuclear reactors) expected to increase content per new reactor by 15–20% (from ~$100M to ~$115–120M).
2026 Guidance and Longer-Term Targets
2026 guidance: reported sales growth 5–7% (organic 1–3%), ~100 bps FX tailwind, ~300 bps benefit from Greenray and Trillium; adjusted operating margin expected to expand ~100 bps; adjusted EPS guidance $4.00–$4.20 (~13% midpoint increase vs 2025). 2030 long-term targets: mid-single-digit organic CAGR (2025–2030) and 20% adjusted operating margins by 2030.
Backlog and Bookings for 2025
Total bookings for 2025 were $4.7 billion, including $400 million in nuclear awards. The company closed the year with a backlog of $2.9 billion and highlighted nearly $100 million of nuclear bookings in the quarter.